cel-sci.com (CVM): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The R&D strategy of CEL-SCI Corporation (CVM) focuses on preparing documentation for head and neck tumor immunotherapy. The company achieves cost optimization through the full outsourcing of production and trials. The market capitalization trend on GURU.Markets recorded a value of 0.00, confirming growth potential. Future revenues for CEL-SCI Corporation (CVM) are based on the market launch of the drug Multikine, making the asset a promising investment opportunity.
CVM (cel-sci.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
- financial results and valuation multiples details:
CVM - Net Income|Projected Future Earnings CEL-SCI Corporation|CVM - Business Payback Period|Projected Price to Earnings CEL-SCI|CVM - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple CEL-SCI Corporation|CVM - Operating profit before deduction of amortization|Earnings per share for the last twelve months CEL-SCI|CVM - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months cel-sci.com|CVM - Earnings per share increase in current year|Net earnings per share growth forecast for next year CEL-SCI Corporation
Summary company analytics:CEL-SCI Corp (CVM)
The EV/EBITDA multiple determines the business value inclusive of net debt relative to operating profit, allowing an investor to assess the real value of an asset without the influence of tax burdens or financing structures. By tracking changes in the EV/EBITDA level of CEL-SCI Corporation (CVM), one can capture how geopolitical instability and sanction restrictions slowing clinical trials impact the market revaluation of its fundamental value.
Main competitors
BeiGene Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Halozyme Corp HALO|RVMD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AAPG (ascentage.com)|CGON: EV/EBITDA Multiple|Company Value to EBITDA UroGen Pharma Ltd (URGN)|BCAX (Bicara Bio) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Personalis Genomics (PSNL)|EV/EBITDA Multiple ERAS|DCTH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Aura Biosciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CADL: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Accuray, Inc. (ARAY)|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|CTOR (Citius Oncology) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio TuHURA (HURA)|EV/EBITDA Multiple TARA|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRX|Champions Oncology Corp - EV/EBITDA Multiple|XBiotech Inc. (XBIT) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Radiopharm Theranostics Ltd (RADX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|ANL: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Company Value to EBITDA|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation KAPA (Kairos Pharma Ltd)|OKUR: EV/EBITDA Multiple|CytoMed Therapeutics Limited (GDTC) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CRIS|APLM (Apollomics Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THAR|Total Company Value to Operating Income Before Depreciation Ratio advanbiomed.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|Calidi Biotherapeutics Inc. (CLDI) - Company Value to EBITDA|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to EBITDA Ratio AONC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BGNE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|EV/EBITDA Multiple ICAD (iCAD)|IKNA - Enterprise Value to EBITDA Ratio|Notable Labs - EV/EBITDA Multiple|VIRX - EV/EBITDA Multiple|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation NAYA|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
